Off-the-shelf donor NK cell therapy showed a safe but non-efficacious profile in small relapsed AML trial.
Phase 1 study of SAR445419 allogeneic NK cell therapy in 7 R/R AML patients (6 received treatment): no dose-limiting toxicities, two grade 2 infusion-related reactions (therapy-related). Five deaths, all from disease progression. No clinical responses observed. Study terminated early for strategic…
Off-the-shelf donor NK cell therapy showed a safe but non-efficacious profile in small relapsed AML trial.
Phase 1 study of SAR445419 allogeneic NK cell therapy in 7 R/R AML patients (6 received treatment): no dose-limiting toxicities, two grade 2 infusion-related reactions (therapy-related). Five deaths, all from disease progression. No clinical responses observed. Study terminated early for strategic reasons unrelated to safety or efficacy.
Key Findings
- No dose-limiting toxicities with SAR445419
- Two therapy-related SAEs (infusion reactions, grade 2)
- Five deaths—all from disease progression, none therapy-related
- No clinical responses observed
- Manufacturing and distribution feasibility demonstrated
Implications
Safety profile supports further NK cell therapy development. Future studies must improve clinical efficacy through engineering, combination strategies, or better patient selection.
Caveats
Very small study (n=6 treated); abstract-only. Early termination limits conclusions. No responses—efficacy is unestablished.
Source: Cancer immunology, immunotherapy : CII — 2026-04-11
